CN102083834A - 用于治疗丙型肝炎的7H-吲哚并[2,1-a][2]苯并氮杂*-10-羧酸衍生物 - Google Patents

用于治疗丙型肝炎的7H-吲哚并[2,1-a][2]苯并氮杂*-10-羧酸衍生物 Download PDF

Info

Publication number
CN102083834A
CN102083834A CN2009801263266A CN200980126326A CN102083834A CN 102083834 A CN102083834 A CN 102083834A CN 2009801263266 A CN2009801263266 A CN 2009801263266A CN 200980126326 A CN200980126326 A CN 200980126326A CN 102083834 A CN102083834 A CN 102083834A
Authority
CN
China
Prior art keywords
alkyl
solvent
mmol
carbonyl
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801263266A
Other languages
English (en)
Chinese (zh)
Inventor
斯科特·W·马丁
卡尔·P·伯格斯特罗姆
丁敏
郑晓帆
罗伯特·G·金特尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40786514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102083834(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102083834A publication Critical patent/CN102083834A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2009801263266A 2008-05-06 2009-05-05 用于治疗丙型肝炎的7H-吲哚并[2,1-a][2]苯并氮杂*-10-羧酸衍生物 Pending CN102083834A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5074308P 2008-05-06 2008-05-06
US61/050,743 2008-05-06
PCT/US2009/042805 WO2009137454A1 (en) 2008-05-06 2009-05-05 7h-indolo[2,1-a] [2] benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
CN102083834A true CN102083834A (zh) 2011-06-01

Family

ID=40786514

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801263266A Pending CN102083834A (zh) 2008-05-06 2009-05-05 用于治疗丙型肝炎的7H-吲哚并[2,1-a][2]苯并氮杂*-10-羧酸衍生物

Country Status (19)

Country Link
US (1) US8133884B2 (cg-RX-API-DMAC7.html)
EP (1) EP2280975B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011520810A (cg-RX-API-DMAC7.html)
KR (1) KR20110015588A (cg-RX-API-DMAC7.html)
CN (1) CN102083834A (cg-RX-API-DMAC7.html)
AR (1) AR071684A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009244409A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0915130A2 (cg-RX-API-DMAC7.html)
CA (1) CA2723683A1 (cg-RX-API-DMAC7.html)
CL (1) CL2009001089A1 (cg-RX-API-DMAC7.html)
CO (1) CO6290645A2 (cg-RX-API-DMAC7.html)
EA (1) EA201001748A1 (cg-RX-API-DMAC7.html)
IL (1) IL208753A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010011921A (cg-RX-API-DMAC7.html)
NZ (1) NZ588556A (cg-RX-API-DMAC7.html)
PE (1) PE20091879A1 (cg-RX-API-DMAC7.html)
TW (1) TW200951135A (cg-RX-API-DMAC7.html)
WO (1) WO2009137454A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007649B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ATE531373T1 (de) 2008-03-27 2011-11-15 Bristol Myers Squibb Co Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092888A2 (en) * 2006-02-08 2007-08-16 Bristol-Myers Squibb Company Hcv ns5b inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080399A1 (ja) 2004-02-24 2005-09-01 Japan Tobacco Inc. 4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
RU2007119562A (ru) 2004-10-26 2008-12-10 Институто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа (It) Тетрациклические производные индолов в качестве противовирусных агентов
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
DE602007006796D1 (de) 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US7652004B2 (en) 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8129367B2 (en) 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092888A2 (en) * 2006-02-08 2007-08-16 Bristol-Myers Squibb Company Hcv ns5b inhibitors

Also Published As

Publication number Publication date
CO6290645A2 (es) 2011-06-20
CA2723683A1 (en) 2009-11-12
WO2009137454A1 (en) 2009-11-12
MX2010011921A (es) 2010-11-30
EP2280975B1 (en) 2014-01-01
US20090280083A1 (en) 2009-11-12
EA201001748A1 (ru) 2011-06-30
CL2009001089A1 (es) 2011-04-29
EP2280975A1 (en) 2011-02-09
AR071684A1 (es) 2010-07-07
NZ588556A (en) 2012-06-29
AU2009244409A1 (en) 2009-11-12
TW200951135A (en) 2009-12-16
IL208753A0 (en) 2010-12-30
KR20110015588A (ko) 2011-02-16
US8133884B2 (en) 2012-03-13
BRPI0915130A2 (pt) 2019-09-24
PE20091879A1 (es) 2009-12-19
ZA201007649B (en) 2012-04-25
JP2011520810A (ja) 2011-07-21

Similar Documents

Publication Publication Date Title
US7473688B2 (en) Indolobenzazepine HCV NS5B inhibitors
JP5232178B2 (ja) C型肝炎の治療のための化合物
US7485633B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
JP5465670B2 (ja) C型肝炎を治療するための化合物
JP5301473B2 (ja) C型肝炎の治療のための化合物
CN101918410B (zh) 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
JP5343011B2 (ja) C型肝炎の治療のための化合物
JP2010521483A (ja) シクロプロピル縮合インドロベンゾアゼピンhcvインヒビター
EP2280975B1 (en) 7h-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c
EP2121694A1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
CN101443336B (zh) 环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂
JP2012517468A (ja) C型肝炎治療のための化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110601